Peptide · developed by Capstone Therapeutics
Chrysalin (TP 508) is a peptide administered by percutaneous injection at the fracture site at the time of surgery. It has been studied in radius fracture, a bone injury of the forearm.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00131482 | Phase 2 | Radius Fracture | Terminated | CAPS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Radius Fracture
Updated Nov 8, 2026. Something wrong or missing? Report it on the CAPS page.
See CAPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CAPS catalysts and pipeline →